Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $2.0 million.

  • Adma Biologics' Depreciation & Amortization (CF) rose 4.28% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 2.63%. This contributed to the annual value of $8.0 million for FY2024, which is 3.44% down from last year.
  • Per Adma Biologics' latest filing, its Depreciation & Amortization (CF) stood at $2.0 million for Q3 2025, which was down 1.70% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Depreciation & Amortization (CF) registered a high of $2.1 million during Q1 2024, and its lowest value of $1.2 million during Q1 2021.
  • Over the past 3 years, Adma Biologics' median Depreciation & Amortization (CF) value was $2.0 million (recorded in 2024), while the average stood at $2.0 million.
  • In the last 5 years, Adma Biologics' Depreciation & Amortization (CF) soared by 55.88% in 2021 and then declined by 7.82% in 2024.
  • Adma Biologics' Depreciation & Amortization (CF) (Quarterly) stood at $1.5 million in 2021, then climbed by 27.55% to $1.9 million in 2022, then rose by 8.91% to $2.1 million in 2023, then dropped by 7.82% to $1.9 million in 2024, then climbed by 4.28% to $2.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.0 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.0 million in Q1 2025.